Zepzelca Lurbinectedin for Injection

1. Indications and Usage
Metastatic Small Cell Lung Cancer (SCLC):
Indicated for the treatment of adult patients with metastatic small cell lung cancer (SCLC) who have disease progression during or after platinum-containing chemotherapy.
Note: This indication is approved under accelerated approval based on objective response rate and duration of response. Continued approval may be contingent upon verification and description of clinical benefit in confirmatory trials.
2. Dosage and Administration
Route of Administration:
Intravenous Infusion ONLY. Do not administer as an IV push or bolus.
Recommended Dosage:
Dose: 3.2 mg/m² administered intravenously over 1 hour.
Frequency: Once every 21 days until disease progression or unacceptable toxicity.
Prerequisites: Ensure Absolute Neutrophil Count (ANC) ≥ 1,500/mm³ and Platelet Count ≥ 100,000/mm³ before starting treatment.
Premedication:
Consider administering antiemetics (e.g., Dexamethasone 8 mg IV or equivalent + Ondansetron 8 mg IV or equivalent) prior to each infusion to prevent nausea and vomiting.
3. Mechanism of Action
DNA Alkylation and Transcription Inhibition:
Lurbinectedin binds to guanine residues in the DNA minor groove, forming adducts that cause bending of the DNA helix. This triggers a cascade of events affecting DNA-binding proteins (including certain transcription factors) and DNA repair pathways, leading to cell cycle arrest and apoptosis.
RNA Polymerase II Inhibition:
It inhibits RNA polymerase II activity, blocking protein synthesis in tumor cells.
4. Safety and Warnings
Myelosuppression:
Can cause severe neutropenia, thrombocytopenia, and anemia. Monitor complete blood counts (CBC) prior to each dose.
Embryo-Fetal Toxicity:
May cause fetal harm. Advise females and males of reproductive potential to use effective contraception during treatment and for at least 6 months (females) or 4 months (males) after the final dose.
Hepatotoxicity:
Monitor liver function tests (ALT/AST) regularly.
Rhabdomyolysis:
Monitor for signs of muscle pain or dark urine.
5. Adverse Reactions
Most Common:
Neutropenia, fatigue, anemia, nausea, decreased appetite, constipation, vomiting, increased creatinine, increased ALT/AST, pyrexia, diarrhea, and cough.
6. Drug Interactions
CYP3A4 Modulators:
Lurbinectedin is metabolized by CYP3A4. Avoid concomitant use with strong CYP3A4 inhibitors or inducers.
Dietary Restrictions:
Avoid grapefruit and grapefruit juice as they inhibit CYP3A4 and may increase drug exposure.
7. Pharmaceutical Information
Chemical Composition:
Active Ingredient: Lurbinectedin (Available in 4 mg lyophilized powder vials).
Storage:
Store in a refrigerator at 2-8°C. Protect from light.